Botting m h (16 Ergebnisse)

Hardcover. Zustand: Good. TENTH IMPRESSION THIRD EDITION. This hardcover edition is in good condition, considering its status as an ex-library copy. The cover shows minor signs of wear, typical of library use, but remains intact and sturdy. There is no dust jacket present. The pages are clean with no inscriptions, maintaining the book's readability and overall integrity.…

Zustand: Good. Volume 3. This is an ex-library book and may have the usual library/used-book markings inside.This book has soft covers. In good all round condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,450grams, ISBN:9781851746279.

Cloth. Zustand: Like New. Zustand des Schutzumschlags: No d/j as Published. Type: Book This volume contains the proceedings of the William Harvey Conference held in London, 10-11 October, 1995. It covers the molecular biology and physiological functions of the cyclo-oxygenase enzymes, as well as the experimental and clinical aspects of the recently discovered inhibitors of the inducible cyclooxygenase. Particular attention has been directed at the discussion of the selectivity of non-steroid anti-inflammatory drugs for cyclooxygenase-2 and their propensity to cause gastric and kidney damage. 248pp.…

Hardcover. Zustand: Near Fine condition. Zustand des Schutzumschlags: No Dust Jacket, as issued. First Edition. Dordrecht, Boston, London:: Kluwer Academic Publishers / William Harvey Press , 1996. Heavy erasure on title page else a bright, clean, square, tight copy. No owner's name or bookplate. No remainder marks. Pages are fresh and crisp. No underlining. No highlighting. No margin notes. Bound in the original maroon, pictorial boards. Proceedings of a Conference Held on October 10-11, 1995, at Regent's College, London. Contains 13 papers: 1) Overview - mechanisms of action of anti-inflammatory drugs; 2) The three-dimensional structure of cyclooxygenases; 3) The dilemma of two-cyclooxygenases: identifying the role of COX-1 and COX-2 in inflammation and apoptosis; 4) Inducible enzymes with special reference to COX-2 in the inflammatory response; 5) NSAID mechanism of action: the role of intracellular pharmacokinetics; 6) Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs; 7) COX-2 expression and inhibition in human monocytes; 8) Expression and regulation of COX-2 in synovial tissues of arthritic patients; 9) An inhibitor of injury-induced COX-2 transcriptional activation elicits neuroprotection in a brain damage model; 10) COX-2 expression in labour; 11) Re-evaluation of gut toxicity of NSAIDs; 12) NSAID: can renal side effects be avoided?; 13) Pharmacology, safety data and therapeutics of COX-2 inhibitors. Bibliographical references. Index. From the rear cover: "This volume is the proceedings of the William Harvey Conference held in London on the 10th and 11th October, 1995. It covers the molecular biology and physiological functions of the cyclooxygenase enzymes, as well as the experimental and clinical aspects of the recently discovered inhibitors of the inducible cyclooxygenase. Particular attention has been directed at the discussion of the selectivity of non-steroid anti-inflammatory drugs for cyclooxygenase-2 and their propensity to cause gastric and kidney damage. Sir John Vane is the Director General, Regina Botting the Information Scientist, and Jack Botting Consultant at the William Harvey Research Institute, an independent charitable foundation carrying out research into cardiovascular disease inflammation and metabolic disorders within Queen Mary and Westfield College of the University of London, UK. Sir John Vane was awarded the Nobel Prize in 1982 for his discoveries of the mechanism of action of aspirin and of the physiological role of prostacyclin and other prostanoids.". First Edition. Hard Cover. Near Fine condition./No Dust Jacket, as issued. 8vo. ix, 241pp.…

Zustand: As New. Unread book in perfect condition.

Zustand: New.

Zustand: New. In English.

Zustand: New. pp. 200.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - In 1971, Vane proposed that the mechanism of action of the aspirin-like drugs was through their inhibition of prostaglandin biosynthesis. Since then, there has been intense interest in the interaction between this diverse group of inhibitors and the enzyme known as cyclooxygenase (COX). It exists in two isoforms, COX-l and COX-2 (discovered some 5 years ago). Over the last two decades several new drugs have reached the market based on COX-l enzyme screens. Elucidation of the three-dimensional structure of COX-l has provided a new understanding for the actions of COX inhibitors. The constitutive isoform of COX, COX-l has clear physiological functions. Its activation leads, for instance, to the production of prostacyclin which when released by the endothelium is anti-thrombogenic and anti-atherosclerotic, and in the gastric mucosa is cyto protective. COX-l also generates prostaglandins in the kidney, where they help to maintain blood flow and promote natriuresis. The inducible isoform, COX-2, was discovered through its activity being increased in a number of cells by pro inflammatory stimuli. A year or so later, COX-2 was identified as a distinct isoform encoded by a different gene from COX-I. COX-2 is induced by inflammatory stimuli and by cytokines in migratory and other cells. Thus the anti-inflammatory actions of non-steroid anti-inflammatory drugs (NSAIDs) may be due to the inhibition of COX-2, whereas the unwanted side-effects such as irritation of the stomach lining and toxic effects on the kidney are due to inhibition of the constitutive enzyme, COX-I.…

Paperback. Zustand: Brand New. reprint edition. 248 pages. 8.75x6.00x0.75 inches. In Stock.

Zustand: new. Questo è un articolo print on demand.

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -In 1971, Vane proposed that the mechanism of action of the aspirin-like drugs was through their inhibition of prostaglandin biosynthesis. Since then, there has been intense interest in the interaction between this diverse group of inhibitors and the enzyme known as cyclooxygenase (COX). It exists in two isoforms, COX-l and COX-2 (discovered some 5 years ago). Over the last two decades several new drugs have reached the market based on COX-l enzyme screens. Elucidation of the three-dimensional structure of COX-l has provided a new understanding for the actions of COX inhibitors. The constitutive isoform of COX, COX-l has clear physiological functions. Its activation leads, for instance, to the production of prostacyclin which when released by the endothelium is anti-thrombogenic and anti-atherosclerotic, and in the gastric mucosa is cyto protective. COX-l also generates prostaglandins in the kidney, where they help to maintain blood flow and promote natriuresis. The inducible isoform, COX-2, was discovered through its activity being increased in a number of cells by pro inflammatory stimuli. A year or so later, COX-2 was identified as a distinct isoform encoded by a different gene from COX-I. COX-2 is induced by inflammatory stimuli and by cytokines in migratory and other cells. Thus the anti-inflammatory actions of non-steroid anti-inflammatory drugs (NSAIDs) may be due to the inhibition of COX-2, whereas the unwanted side-effects such as irritation of the stomach lining and toxic effects on the kidney are due to inhibition of the constitutive enzyme, COX-I. 264 pp. Englisch.…

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology o. …

Zustand: New. Print on Demand pp. 200.

Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -In 1971, Vane proposed that the mechanism of action of the aspirin-like drugs was through their inhibition of prostaglandin biosynthesis. Since then, there has been intense interest in the interaction between this diverse group of inhibitors and the enzyme known as cyclooxygenase (COX). It exists in two isoforms, COX-l and COX-2 (discovered some 5 years ago). Over the last two decades several new drugs have reached the market based on COX-l enzyme screens. Elucidation of the three-dimensional structure of COX-l has provided a new understanding for the actions of COX inhibitors. The constitutive isoform of COX, COX-l has clear physiological functions. Its activation leads, for instance, to the production of prostacyclin which when released by the endothelium is anti-thrombogenic and anti-atherosclerotic, and in the gastric mucosa is cyto protective. COX-l also generates prostaglandins in the kidney, where they help to maintain blood flow and promote natriuresis. The inducible isoform, COX-2, was discovered through its activity being increased in a number of cells by pro inflammatory stimuli. A year or so later, COX-2 was identified as a distinct isoform encoded by a different gene from COX-I. COX-2 is induced by inflammatory stimuli and by cytokines in migratory and other cells. Thus the anti-inflammatory actions of non-steroid anti-inflammatory drugs (NSAIDs) may be due to the inhibition of COX-2, whereas the unwanted side-effects such as irritation of the stomach lining and toxic effects on the kidney are due to inhibition of the constitutive enzyme, COX-I.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 264 pp. Englisch.…

Zustand: New. PRINT ON DEMAND pp. 200.